Quick Answer
Monte Rosa Therapeutics, Inc. reported Net Income of -$38.63 million for fiscal year 2025.
Monte Rosa Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$38.63M +46.9% |
-$72.70M +46.3% |
-$135.35M -24.7% |
-$108.50M -46.7% |
-$73.96M -106.1% |
-$35.88M |
| Total Assets | $448.66M +2.3% |
$438.73M +44.4% |
$303.75M -11.3% |
$342.39M -6.5% |
$366.33M +641.9% |
$49.38M |
| Cash and Equivalents | $129.88M -42.1% |
$224.25M +75.1% |
$128.10M +133.3% |
$54.91M -84.1% |
$346.07M +729.9% |
$41.70M |
| Stockholders Equity | $233.06M +4.5% |
$222.94M +24.4% |
$179.25M -34.0% |
$271.41M -21.9% |
$347.51M +813.2% |
-$48.73M |
| R&D Expense | $141.50M +16.4% |
$121.56M +9.2% |
$111.27M +30.8% |
$85.06M +48.8% |
$57.16M +138.1% |
$24.00M |
| Operating Income | -$54.21M +33.2% |
-$81.11M +43.4% |
-$143.31M -27.5% |
-$112.38M -54.2% |
-$72.88M -160.2% |
-$28.01M |
| Shares Outstanding | 65.54M +6.6% |
61.51M +22.7% |
50.14M +1.7% |
49.32M +6.0% |
46.54M +2660.9% |
1.69M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$27.08M | -13.5% | -120.3% |
| Total Assets | September 30, 2025 | $459.84M | +45.9% | +27.9% |
| Cash and Equivalents | September 30, 2025 | $208.34M | +65.9% | +200.1% |
| Stockholders Equity | September 30, 2025 | $245.84M | +19.7% | -8.3% |
| R&D Expense | September 30, 2025 | $36.68M | +32.8% | +19.7% |
| Operating Income | September 30, 2025 | -$32.98M | -24.3% | -112.0% |
| Shares Outstanding | September 30, 2025 | 61.79M | +0.7% | +0.1% |
- Monte Rosa Therapeutics, Inc. reported Net Income of -$38.63 million for fiscal year 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +46.9% in Net Income compared to the prior fiscal year.
- Monte Rosa Therapeutics, Inc. reported Total Assets of $448.66 million for fiscal year 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +2.3% in Total Assets compared to the prior fiscal year.
- Monte Rosa Therapeutics, Inc. reported Cash and Equivalents of $129.88 million for fiscal year 2025.
- Monte Rosa Therapeutics, Inc. showed a decrease of -42.1% in Cash and Equivalents compared to the prior fiscal year.
- Monte Rosa Therapeutics, Inc. reported Stockholders Equity of $233.06 million for fiscal year 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +4.5% in Stockholders Equity compared to the prior fiscal year.
- Monte Rosa Therapeutics, Inc. reported R&D Expense of $141.50 million for fiscal year 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +16.4% in R&D Expense compared to the prior fiscal year.
- Monte Rosa Therapeutics, Inc. reported Operating Income of -$54.21 million for fiscal year 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +33.2% in Operating Income compared to the prior fiscal year.
- Monte Rosa Therapeutics, Inc. reported Shares Outstanding of 65.54 million shares for fiscal year 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +6.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: